Investment Thesis
Fortress Biotech exhibits severe operational losses (-138.7% operating margin) with negative free cash flow of -$53.2M, indicating the company is burning cash despite modest revenue growth of 4.6%. The disconnect between negative operating income and positive net income raises concerns about sustainability, and the company's cash runway will be critical to monitor given ongoing operational cash burn.
Strengths
- Strong liquidity position with $86.2M in cash and 2.19x current ratio providing near-term operational runway
- Positive net margin of 22.8% and growing net income (+17.7% YoY) suggest potential profitability improvement trajectory
- Moderate leverage at 0.86x debt-to-equity ratio with reasonable balance sheet structure
Risks
- Severe operating losses of -$65.4M with operating margin of -138.7% indicating core business is unprofitable at scale
- Significant negative free cash flow of -$53.2M (-112.8% FCF margin) means the company is burning through cash reserves at an unsustainable rate
- Operating cash flow negative at -$53.2M while net income is positive suggests earnings quality concerns and potential non-cash gains masking operational deterioration
- Cash burn rate of approximately $53M annually means current $86.2M cash balance provides less than 2 years of runway without achieving positive operations
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Cash runway and burn rate relative to milestone achievements
- Operating margin progression and evidence of cost control initiatives
- Revenue growth acceleration needed to reach profitability at current cost structure
Financial Metrics
Revenue
47.2M
Net Income
10.8M
EPS (Diluted)
$0.14
Free Cash Flow
-53.2M
Total Assets
181.4M
Cash
86.2M
Profitability Ratios
Gross Margin
7.4%
Operating Margin
-138.7%
Net Margin
22.8%
ROE
19.2%
ROA
5.9%
FCF Margin
-112.8%
Balance Sheet & Liquidity
Current Ratio
2.19x
Quick Ratio
1.97x
Debt/Equity
0.86x
Debt/Assets
64.1%
Interest Coverage
-8.11x
Long-term Debt
47.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T18:22:11.942201 |
Data as of: 2025-09-30 |
Powered by Claude AI